These proteomic changes, particularly in neuro-associated proteins such as Prnp and Synpo, suggest that CSPG4-targeted therapy may influence neurocardiac signaling pathways disrupted in DMD. This evidence concerns the gene CSPG4 and Duchenne muscular dystrophy.